1 Min Read Eosinophils: The Parasite Killers
July 27, 2026Core Framework & Diagram Eosinophils: The Parasite Killers
July 27, 2026Eosinophils are specialists against parasites — but in modern life, they often attack the wrong target
—— Why allergies keep rising: an ancient immune mechanism looking for an enemy that's almost disappeared.
I. A cell designed to fight an enemy you may never have encountered
If you live in a modern city, you've probably never had a genuine large parasite infection — roundworms, hookworms, schistosomes, the kinds of helminths that live inside human bodies.
Yet your immune system contains a cell whose entire existence is designed to fight exactly these enemies: the eosinophil. The name comes from its affinity for the dye eosin — under a microscope it stains a distinctive orange-red, making it easy to identify.
For most of human evolutionary history, intestinal parasite infection was nearly universal. These parasites are enormous in size — neutrophils and macrophages can't swallow them. Eosinophils' solution: press against the parasite's surface, then release highly toxic proteins — Major Basic Protein (MBP), Eosinophil Cationic Protein (ECP), Eosinophil-Derived Neurotoxin (EDN) — directly damaging the parasite's exterior and killing it.
This is a precision defensive mechanism against 'large extracellular pathogens,' highly effective in the era when parasitic infection was universal. The problem: in our clean, nearly parasite-free modern environments, eosinophils have lost their original opponents — but not their activation mechanisms.
2. . Th2 immune response: the context for eosinophil activation
To understand eosinophils' role in allergy, you need the background concept of Th2-type immune response. CD4+ helper T cells can differentiate into different functional subtypes: Th1 primarily targets intracellular pathogens (viruses, tuberculosis); Th2 primarily targets large extracellular pathogens, especially parasites.
The Th2 response is characterized by large production of three cytokines: IL-4 (drives B cells to switch antibody class from IgG to IgE); IL-5 (the 'command' for eosinophils — tells bone marrow to produce more and tells existing eosinophils to increase activation state); and IL-13 (promotes increased mucus secretion and airway hyperreactivity).
Against parasites, this Th2 combined-arms system is precisely designed: IgE coats mast cells and eosinophils to 'target' them; IL-5 ensures enough eosinophils arrive at the infection site; eosinophils surround the parasite and release toxic proteins. In allergic individuals, however, this Th2 response is incorrectly activated by harmless environmental substances (pollen, dust mites, food proteins, pet dander). IgE forms against harmless substances; eosinophils are activated by IL-5 and accumulate in the airways or skin; toxic proteins are released into the body's own tissue — this is the core mechanism of allergic asthma, allergic rhinitis, and atopic dermatitis.
3. How neutrophils travel from blood to infection site
Asthma affects over 300 million people globally. Many know it's airway inflammation, but fewer know that eosinophils are one of the primary drivers of that inflammation.
In typical allergic asthma, an allergen enters the airway, triggers Th2 response, IL-5 is released massively, and eosinophils are recruited from blood in large numbers to the airway mucosa. These eosinophils accumulate in the airway, releasing MBP, ECP, and other toxic proteins that damage airway epithelial cells, triggering airway remodeling (thickened airway walls, smooth muscle proliferation) and airway hyperreactivity.
Long-term eosinophilic airway inflammation is the core mechanism behind the progressive irreversible structural changes in asthmatic airways. This explains why inhaled corticosteroids (like budesonide) are the cornerstone of asthma treatment — one of their most important effects is suppressing eosinophil accumulation in the airway.
Recent advances in biological therapy for severe eosinophilic asthma have been significant: anti-IL-5 monoclonal antibodies (mepolizumab, benralizumab) directly block IL-5 signaling, fundamentally reducing eosinophil production and activation, showing remarkable efficacy in steroid-dependent severe asthma. This is a successful case of precision immunotherapy: identifying the core 'wrong command' (IL-5) and precisely cutting it off.
4. Hygiene hypothesis: why allergies keep rising in modern cities
Over the past several decades, allergy incidence has continuously risen in developed countries — asthma, hay fever, food allergies, atopic dermatitis, all increasing. Why?
In 1989, British epidemiologist David Strachan proposed the 'Hygiene Hypothesis' — now supported by substantial evidence, though still evolving.
The core observation: children who grew up on farms, with more siblings, and with more childhood infections have significantly lower rates of allergies and autoimmune diseases in adulthood compared to urban only-children raised in overly clean environments.
Why? Because the immune system — particularly the regulatory mechanisms controlling Th1/Th2 balance — needs 'training.' In the microorganism and parasite-rich environments humans evolved in, abundant Th1 stimulation (from various infections) continuously 'held down' the Th2 response, maintaining immune balance. In modern overly clean environments, Th1 stimulation is greatly reduced (fewer infections). The Th2 response loses its counterweight on the other side of the scale and becomes relatively overactive, mounting unnecessary Th2 responses against harmless environmental substances — the result is allergy.
A more modern version is called the 'Old Friends Hypothesis': the key isn't just microbial quantity, but specific types of 'old friends' — organisms we co-evolved with for millions of years (especially gut microbiota) and certain parasites — that are necessary partners for training the immune system to respond correctly. Losing these 'old friends' leaves eosinophils without the correct training ground.
5. NElevated eosinophils on blood count: reading this number
Normal eosinophil range on a blood count is typically 0.02–0.5×10⁹/L (1–5% of white cells). Elevated counts warrant attention, but the cause requires careful differentiation.
Mild elevation (0.5–1.5×10⁹/L): the most common causes are allergic diseases (hay fever, asthma, atopic dermatitis, food allergy), followed by parasitic infections (more common in developing countries) and drug reactions.
Moderate elevation (1.5–5×10⁹/L): in addition to the above, rule out parasitic infections (especially with travel history) and autoimmune diseases (eosinophilic esophagitis, eosinophilic gastroenteritis).
Severe elevation (>5×10⁹/L) — hypereosinophilic syndrome: at this level, eosinophils can directly damage the heart, lungs, nerves, and skin, because large numbers accumulate in these tissues and continuously release toxic proteins. This requires serious diagnosis and treatment; causes include certain blood malignancies (eosinophilic leukemia), severe parasitic infection, and idiopathic hypereosinophilic syndrome.
Frequently Asked Questions